An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII
Year: 2025
Type: article
Language: en
Topic: Monoclonal and Polyclonal Antibodies Research
Authors and affiliations:
raw_author_name: Elisabeth Husar
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland. Electronic address: elisabeth.husar@roche.com
raw_author_name: Silke Simon
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Afsaneh Abdolzade-Bavil
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Munich, 82377, Penzberg, Germany
raw_author_name: Angelique Augustin
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Miro J. Eigenmann
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Anne Freimoser-Grundschober
raw_affiliation_strings: Roche Pharma Research & Early Development, Innovation Center Zürich, 8952, Schlieren, Switzerland
raw_author_name: Alina Gavrilov
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Reto Gianotti
raw_affiliation_strings: Roche Pharma Research & Early Development, Innovation Center Zürich, 8952, Schlieren, Switzerland
raw_author_name: Nikolche Gjorevski
raw_affiliation_strings: Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland
raw_author_name: Patricio Godoy
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Andreas Hollenstein
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Martin Lechmann
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Munich, 82377, Penzberg, Germany
raw_author_name: Valeria G. Nicolini
raw_affiliation_strings: Roche Pharma Research & Early Development, Innovation Center Zürich, 8952, Schlieren, Switzerland
raw_author_name: Liudmila Polonchuk
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Nadine Stokar-Regenscheit
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Roberto Villaseñor
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
raw_author_name: Cornelia Wagner
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Munich, 82377, Penzberg, Germany
raw_author_name: Inja Waldhauer
raw_affiliation_strings: Roche Pharma Research & Early Development, Innovation Center Zürich, 8952, Schlieren, Switzerland
raw_author_name: Antje-Christine Walz
raw_affiliation_strings: Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland; tkc suisse GmbH, 4126 Bettingen, Switzerland